It has been reported in multiple lupus studies [63], [64] that the presence of aCL (IgG) antibodies in lupus patients especially those with APS syndrome, are associated with poor prognosis, increased mortality, and an earlier time of onset of several criteria, in particular malar rash and nephritis. The gene discussed is ACLY; the disease is nephritis.